Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, has closed $15.1 million as part of a Series B-1 financing round expected to reach about $19 million…click here to continue reading
Press Releases
Home > Press Releases > ASPYRIAN THERAPEUTICS INC. CLOSES $15.1M AS PART OF A SERIES B-1 FINANCING TO SUPPORT THE ADVANCEMENT OF ITS PROPRIETARY PRECISION TARGETED THERAPY, RM-1929 TO LATE STAGE CLINICAL DEVELOPMENT AND THE PROGRESSION OF NEW PROPRIETARY IMMUNE ONCOLOGY ASSETS INTO THE CLINIC
Pipeline
Pipeline
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
© Rakuten Medical Inc. 2022, All rights reserved.